对重症血友病 A 进行长效血友病α与八肽血友病α的综合实验室评估。

IF 3 2区 医学 Q2 HEMATOLOGY Haemophilia Pub Date : 2024-08-20 DOI:10.1111/hae.15089
Jens Müller, Thilo Albert, Claudia Klein, Silvia Horneff, Heiko Rühl, Bernd Pötzsch, Georg Goldmann, Natascha Marquardt, Johannes Oldenburg
{"title":"对重症血友病 A 进行长效血友病α与八肽血友病α的综合实验室评估。","authors":"Jens Müller,&nbsp;Thilo Albert,&nbsp;Claudia Klein,&nbsp;Silvia Horneff,&nbsp;Heiko Rühl,&nbsp;Bernd Pötzsch,&nbsp;Georg Goldmann,&nbsp;Natascha Marquardt,&nbsp;Johannes Oldenburg","doi":"10.1111/hae.15089","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Lonoctocog alfa is a single-chain factor VIII (FVIII) molecule with high binding affinity to von-Willebrand-factor. While it is well known that its plasma activity is underestimated by one-stage clotting assays (OSCA), there is a lack of knowledge on the post-infusion performance of lonoctocog alfa in global coagulation assays or its potential impact on the haemostatic balance in vivo.</p>\n </section>\n \n <section>\n \n <h3> Aim</h3>\n \n <p>To characterize lonoctocog alfa versus octocog alfa in pre- and post-infusion samples obtained from patients undergoing repeated investigation of incremental recovery (IR).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Eighteen patients with severe haemophilia A (lonoctocog alfa: 10, octocog alfa: 8) were included. A panel of factor-specific and global coagulation assays was applied, comprising a FVIII OSCA, two FVIII chromogenic substrate assays (CSA), rotational thrombelastography and thrombin generation (TG). Potential activation of coagulation was assessed by measuring plasma thrombin markers and levels of activated protein C.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Comparable IRs were found for lonoctocog alfa and octocog alfa (2.36 [IU/dL]/[IU/kg] vs. 2.55 [IU/dL]/[IU/kg], respectively). Lonoctocog alfa activities were found to be underestimated by the FVIII OSCA while also the two FVIII CSAs showed statistically significant assay discrepancies on lonoctocog alfa. Effects of both FVIII products on rotational thrombelastography were less distinct than those on TG parameters. No elevated pre- or significantly shifting post-infusion plasma levels of coagulation biomarkers were detected.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Lonoctocog alfa and octocog alfa showed comparable recovery and safety in vivo as well as similar impacts on TG in vitro. Observed assay discrepancies on lonoctocog alfa demonstrated variability of results also between different FVIII CSAs.</p>\n </section>\n </div>","PeriodicalId":12819,"journal":{"name":"Haemophilia","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hae.15089","citationCount":"0","resultStr":"{\"title\":\"Comprehensive laboratory assessment of lonoctocog alfa versus octocog alfa in severe haemophilia A\",\"authors\":\"Jens Müller,&nbsp;Thilo Albert,&nbsp;Claudia Klein,&nbsp;Silvia Horneff,&nbsp;Heiko Rühl,&nbsp;Bernd Pötzsch,&nbsp;Georg Goldmann,&nbsp;Natascha Marquardt,&nbsp;Johannes Oldenburg\",\"doi\":\"10.1111/hae.15089\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>Lonoctocog alfa is a single-chain factor VIII (FVIII) molecule with high binding affinity to von-Willebrand-factor. While it is well known that its plasma activity is underestimated by one-stage clotting assays (OSCA), there is a lack of knowledge on the post-infusion performance of lonoctocog alfa in global coagulation assays or its potential impact on the haemostatic balance in vivo.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Aim</h3>\\n \\n <p>To characterize lonoctocog alfa versus octocog alfa in pre- and post-infusion samples obtained from patients undergoing repeated investigation of incremental recovery (IR).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Eighteen patients with severe haemophilia A (lonoctocog alfa: 10, octocog alfa: 8) were included. A panel of factor-specific and global coagulation assays was applied, comprising a FVIII OSCA, two FVIII chromogenic substrate assays (CSA), rotational thrombelastography and thrombin generation (TG). Potential activation of coagulation was assessed by measuring plasma thrombin markers and levels of activated protein C.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Comparable IRs were found for lonoctocog alfa and octocog alfa (2.36 [IU/dL]/[IU/kg] vs. 2.55 [IU/dL]/[IU/kg], respectively). Lonoctocog alfa activities were found to be underestimated by the FVIII OSCA while also the two FVIII CSAs showed statistically significant assay discrepancies on lonoctocog alfa. Effects of both FVIII products on rotational thrombelastography were less distinct than those on TG parameters. No elevated pre- or significantly shifting post-infusion plasma levels of coagulation biomarkers were detected.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Lonoctocog alfa and octocog alfa showed comparable recovery and safety in vivo as well as similar impacts on TG in vitro. Observed assay discrepancies on lonoctocog alfa demonstrated variability of results also between different FVIII CSAs.</p>\\n </section>\\n </div>\",\"PeriodicalId\":12819,\"journal\":{\"name\":\"Haemophilia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-08-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hae.15089\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Haemophilia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/hae.15089\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haemophilia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hae.15089","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

简介Lonoctocog alfa 是一种单链因子 VIII (FVIII) 分子,与 von-Willebrand 因子的结合亲和力很高。众所周知,单阶段凝血测定法(OSCA)低估了其血浆活性,但人们对长链苜蓿在全凝血测定法中的输注后表现或其对体内止血平衡的潜在影响还缺乏了解。目的:对接受增量恢复(IR)反复调查的患者输注前和输注后样本中的长链苜蓿与八链苜蓿进行比较:共纳入18名重症血友病A患者(lonoctocog alfa:10人,octocog alfa:8人)。采用了一组特异性因子和整体凝血测定,包括 FVIII OSCA、两种 FVIII 色原底物测定(CSA)、旋转凝血活酶图和凝血酶生成(TG)。通过测量血浆凝血酶标记物和活化蛋白 C 的水平来评估潜在的凝血活化:结果:发现lonoctocog alfa和octocog alfa的IR值相当(分别为2.36 [IU/dL]/[IU/kg]对2.55 [IU/dL]/[IU/kg])。FVIII OSCA低估了lonoctocog alfa的活性,而两种FVIII CSA对lonoctocog alfa的检测差异也具有统计学意义。两种 FVIII 产品对旋转凝血活酶图的影响不如对 TG 参数的影响明显。未发现输注前血浆凝血生物标志物水平升高或输注后血浆凝血生物标志物水平发生明显变化:结论:lonoctocog alfa 和 octocog alfa 在体内显示出相似的恢复性和安全性,在体外对 TG 的影响也相似。观察到的 lonoctocog alfa 检测差异表明,不同 FVIII CSAs 的检测结果也存在差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Comprehensive laboratory assessment of lonoctocog alfa versus octocog alfa in severe haemophilia A

Introduction

Lonoctocog alfa is a single-chain factor VIII (FVIII) molecule with high binding affinity to von-Willebrand-factor. While it is well known that its plasma activity is underestimated by one-stage clotting assays (OSCA), there is a lack of knowledge on the post-infusion performance of lonoctocog alfa in global coagulation assays or its potential impact on the haemostatic balance in vivo.

Aim

To characterize lonoctocog alfa versus octocog alfa in pre- and post-infusion samples obtained from patients undergoing repeated investigation of incremental recovery (IR).

Methods

Eighteen patients with severe haemophilia A (lonoctocog alfa: 10, octocog alfa: 8) were included. A panel of factor-specific and global coagulation assays was applied, comprising a FVIII OSCA, two FVIII chromogenic substrate assays (CSA), rotational thrombelastography and thrombin generation (TG). Potential activation of coagulation was assessed by measuring plasma thrombin markers and levels of activated protein C.

Results

Comparable IRs were found for lonoctocog alfa and octocog alfa (2.36 [IU/dL]/[IU/kg] vs. 2.55 [IU/dL]/[IU/kg], respectively). Lonoctocog alfa activities were found to be underestimated by the FVIII OSCA while also the two FVIII CSAs showed statistically significant assay discrepancies on lonoctocog alfa. Effects of both FVIII products on rotational thrombelastography were less distinct than those on TG parameters. No elevated pre- or significantly shifting post-infusion plasma levels of coagulation biomarkers were detected.

Conclusion

Lonoctocog alfa and octocog alfa showed comparable recovery and safety in vivo as well as similar impacts on TG in vitro. Observed assay discrepancies on lonoctocog alfa demonstrated variability of results also between different FVIII CSAs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Haemophilia
Haemophilia 医学-血液学
CiteScore
6.50
自引率
28.20%
发文量
226
审稿时长
3-6 weeks
期刊介绍: Haemophilia is an international journal dedicated to the exchange of information regarding the comprehensive care of haemophilia. The Journal contains review articles, original scientific papers and case reports related to haemophilia care, with frequent supplements. Subjects covered include: clotting factor deficiencies, both inherited and acquired: haemophilia A, B, von Willebrand''s disease, deficiencies of factor V, VII, X and XI replacement therapy for clotting factor deficiencies component therapy in the developing world transfusion transmitted disease haemophilia care and paediatrics, orthopaedics, gynaecology and obstetrics nursing laboratory diagnosis carrier detection psycho-social concerns economic issues audit inherited platelet disorders.
期刊最新文献
The impact of emicizumab on the clinical validation of new therapies for haemophilia A. The haemophilia joint health score for the assessment of joint health in patients with haemophilia. Performance of instrumental activities of daily living in patients with haemophilic arthropathy. A cross-sectional cohort study. A novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary results. Breaking barriers in haemophilia A care: One-year real-world experience with emicizumab prophylaxis at Civil Service Hospital, Kathmandu, Nepal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1